Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism

Circulation

Volumn 107, Issue 1, 2003, Pages 17-20

  Undas, Anetta ^a   Sydor, Wojciech J ^a   Brummel, Kathleen ^b   Musial, Jacek ^a   Mann, Kenneth G ^b   Szczeklik, Andrew ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b NONE

Author keywords

Aspirin; Coagulation; Genetics

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING INHIBITOR; LEUCINE; THROMBIN; VALINE;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; HEART INFARCTION; HEART PROTECTION; HOMOZYGOSITY; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MICROVASCULAR SURGERY; PRIORITY JOURNAL; THROMBIN TIME; WESTERN BLOTTING;

ADULT; ASPIRIN; BLEEDING TIME; BLOOD COAGULATION; BLOTTING, WESTERN; CARDIOTONIC AGENTS; FACTOR XIII; FACTOR XIIIA; HUMANS; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0037422559     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000047062.03282.A3     Document Type: Article

References (13)

1. Kohler HP, Stickland MH, Ossei-Gerning N, et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 1998;79:8-13.
2. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001;936:291-311.
3. Ariëns RAS, Phillipou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96:988-995.
4. Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor V34L mutation. J Biol Chem. 2000;275:20627-20631.
5. He S, Blomback M, Too G, et al. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann N Y Acad Sci. 2001;936:531-535.
6. Balogh I, Szôke G, Kárpáti L, et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood. 2000;96:2479-2486.
7. Szczeklik A, Krzanowski M, Góra P, et al. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 1992;80:2006-2011.
8. Undas A, Brummel K, Musial J, et al. Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood. 2001;98:2423-2431.
9. Weiss JH, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood. 1988;71:629-635.
10. Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature. 1968;219:68-72.
11. Winocour PD, Watala C, Perry DW, et al. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost. 1992;68:577-582.
12. Björnsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis: fibrinolytic effect is independent of changes in plasminogen activator levels. J Parmacol Exp Ther. 1989;250:154-161.
13. 3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001;104:2666-2672.